About Tissue Regenix
Tissue Regenix is a company based in Swillington (United Kingdom) founded in 2006.. Tissue Regenix has completed 1 acquisition, including CellRight Technologies. Tissue Regenix offers products and services including DermaPure®, OrthoPure® XT, MatrixCellect, Matrix IQ® Dermis, and Matrix OI®. Tissue Regenix operates in a competitive market with competitors including Humacyte, MiMedx Group, Ossio, EpiBone and Biocomposites, among others.
- Headquarter Swillington, United Kingdom
- Stage Public
-
Sectors
Aerospace, Defense & MaritimeHealthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tissue Regenix Group Plc
-
Annual Revenue
$28.09 M (USD)5.89as on Dec 31, 2024
-
Net Profit
$-699.11 K (USD)59.51as on Dec 31, 2024
-
EBITDA
$1.42 M (USD)288.31as on Dec 31, 2024
-
Latest Funding Round
$10.07 M (USD), Post-IPO
Dec 23, 2025
-
Investors
IP Group
& 1 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tissue Regenix
Tissue Regenix is a publicly listed company on the LSE with ticker symbol TRX in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Tissue Regenix
Tissue Regenix offers a comprehensive portfolio of products and services, including DermaPure®, OrthoPure® XT, MatrixCellect, Matrix IQ® Dermis, and Matrix OI®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Regenerative product for skin repair in surgical applications.
Solution for bone and tissue regeneration in orthopaedic treatments.
Device for regenerative procedures in dental care.
Product for dermal matrix applications in regenerative medicine.
Regenerative material for bone repair and fillers.
Unlock access to complete
Unlock access to complete
Funding Insights of Tissue Regenix
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $10.1M
-
First Round
First Round
(22 Jan 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Post-IPO - Tissue Regenix | Valuation |
investors |
|
| May, 2020 | Amount | Post-IPO - Tissue Regenix | Valuation |
investors |
|
| Jun, 2019 | Amount | Debt – Conventional - Tissue Regenix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tissue Regenix
Tissue Regenix has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include IP Group and Harwood Private Equity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and advisory services are offered across multiple sectors.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tissue Regenix
Tissue Regenix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CellRight Technologies. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Orthobiologic scaffolds are developed for regenerative orthopedic therapies.
|
2011 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Tissue Regenix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tissue Regenix Comparisons
Competitors of Tissue Regenix
Tissue Regenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Humacyte, MiMedx Group, Ossio, EpiBone and Biocomposites, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Human tissue-based products are developed for vascular disease applications.
|
|
| domain | founded_year | HQ Location |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
|
| domain | founded_year | HQ Location |
Orthopedic fixation is enabled by bone regeneration biocomposite technology.
|
|
| domain | founded_year | HQ Location |
Developer of stem cells to regrow damaged bones
|
|
| domain | founded_year | HQ Location |
Synthetic calcium composites are developed for bone repair and regeneration.
|
|
| domain | founded_year | HQ Location |
Biological drugs for skin and mucosa wound treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tissue Regenix
Frequently Asked Questions about Tissue Regenix
When was Tissue Regenix founded?
Tissue Regenix was founded in 2006 and raised its 1st funding round 9 years after it was founded.
Where is Tissue Regenix located?
Tissue Regenix is headquartered in Swillington, United Kingdom. It is registered at Swillington, England, United Kingdom.
Who is the current CEO of Tissue Regenix?
Steve Couldwell is the current CEO of Tissue Regenix.
What is the annual revenue of Tissue Regenix?
Annual revenue of Tissue Regenix is $28.09M as on Dec 31, 2024.
What does Tissue Regenix do?
Tissue Regenix was founded in 2006 in Swillington, United Kingdom, within the regenerative medicine sector. Patented dCELL technology is employed to remove DNA and cellular material from tissues, creating acellular scaffolds, while BioRinse technology provides inductive bone allografts. These products are utilized in applications such as chronic wound healing, damaged valve replacement, joint repair, and vascular surgery procedures.
Who are the top competitors of Tissue Regenix?
Tissue Regenix's top competitors include Humacyte, EpiBone and Theradaptive.
What products or services does Tissue Regenix offer?
Tissue Regenix offers DermaPure®, OrthoPure® XT, MatrixCellect, Matrix IQ® Dermis, and Matrix OI®.
Is Tissue Regenix publicly traded?
Yes, Tissue Regenix is publicly traded on LSE under the ticker symbol TRX.
How many acquisitions has Tissue Regenix made?
Tissue Regenix has made 1 acquisition, including CellRight Technologies.
Who are Tissue Regenix's investors?
Tissue Regenix has 2 investors. Key investors include IP Group, and Harwood Private Equity.
What is Tissue Regenix's ticker symbol?
The ticker symbol of Tissue Regenix is TRX on LSE.